Immunotherapy with Y90-radioembolization for metastatic colorectal cancer (iRE-C).

Overview of attention for article published in Journal of Clinical Oncology, February 2020

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (68th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 10 X users

Readers on

mendeley: 14 Mendeley

So far, Altmetric has seen 14 X posts from 10 X users, with an upper bound of 90,254 followers.

RT @pashtoonkasi: @AmmarSarwarIRad @ben_schlechter @aparna1024 @sepideh_gholami @OncoAlert My phase-1 called the iRE-C study is complete wi…

@AmmarSarwarIRad @ben_schlechter @aparna1024 @sepideh_gholami @OncoAlert My phase-1 called the iRE-C study is complete without any safety issues. We sandwiched the Y90☢️ around 5 doses of immunotherapy. Accelerated titration design. Liver may need altern…

RT @RenoHemonc: @ggreen1986 dosimetry based Y 90 data for CRC available?

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 10 additional X posts.